Alligator Bioscience agrees to sell mitazalimab to Biossil

• Alligator Bioscience agreed to sell worldwide rights to mitazalimab to Biossil for USD 750,000 upfront.
• Contingent milestones total up to USD 108 million: USD 3 million for US/EU approvals; USD 105 million tied to worldwide sales.
• The seller also retains mid-single-digit royalties on worldwide net sales, capped at USD 250 million.
• A sale or license to a third party within two years of signing would entitle the seller to a share of proceeds.
• Closing is expected within 30 days of signing, with Biossil assuming all further development, manufacturing and patent costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alligator Bioscience AB published the original content used to generate this news brief on October 31, 2026, and is solely responsible for the information contained therein.